Current Report Filing (8-k)

Date : 05/09/2018 @ 8:20AM
Source : Edgar (US Regulatory)
Stock : Endocyte, Inc. (ECYT)
Quote : 17.63  0.09 (0.51%) @ 6:00PM
Endocyte, Inc. share price Chart

Current Report Filing (8-k)

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): May 3, 2018

 

 

 

 

 

Endocyte, Inc. 

 

 

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

 

Delaware

 

001-35050

 

35-1969-140

(State or other jurisdiction

 

(Commission

 

(I.R.S. Employer

of incorporation)

 

File Number)

 

Identification No.)

 

 

 

 

 

3000 Kent Avenue, Suite A1-100, 
West Lafayette, Indiana

 

47906

(Address of principal executive offices)

 

(Zip Code)

 

 

 

 

Registrant’s telephone number, including area code:

765-463-7175

 

 

 

 

 

 

Not Applicable

 

 

Former name or former address, if changed since last report

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 


 

 

ITEM 2.02  Results of Operations and Financial Condition.

 

On May 9, 2018, Endocyte, Inc. (the “Company”) announced its results of operations for the three months ended March 31, 2018. A copy of the Company’s earnings release is furnished herewith as Exhibit 99.1.

 

The information in this Item 2.02 and in Item 9.01 of this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and in Item 9.01 of this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.  

 

ITEM 5.07  Submission of Matters to a Vote of Security Holders.

 

The Company held its 2018 annual meeting of stockholders on May 3, 2018. The Company’s stockholders took the following actions on the business items which were set forth in the notice for the meeting:

 

Proposal 1 – Election of Directors: elected three (3) directors for three-year terms ending at the 2021 annual meeting of stockholders;

 

Proposal 2 – Ratification of Independent Registered Public Accounting Firm: ratified the Audit Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2018;

 

Proposal 3 – Advisory Vote on Executive Compensation (“Say-on-Pay”): approved the compensation of the Named Executive Officers.

 

The vote tabulation for each proposal is as follows:

 

Proposal 1 – Election of Directors

 

 

 

 

 

 

 

 

 

 

 

 

Nominee

 

For

 

 

Withhold

 

 

Broker
Non-Votes

Patrick Machado

 

 

36,471,268

 

 

 

83,550

 

 

 

13,199,282

Lesley Russell

 

 

36,470,775

 

 

 

84,043

 

 

 

13,199,282

Dawn Svoronos

 

 

36,465,278

 

 

 

89,540

 

 

 

13,199,282

 

 

Proposal 2 – Ratification of Independent Registered Public Accounting Firm

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

49,455,655

 

 

 

45,402

 

 

 

253,043

 

 

 

0

 

 

Proposal 3 – Advisory Vote on Executive Compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For

 

 

Against

 

 

Abstain

 

 

Broker Non-Votes

 

36,268,657

 

 

 

129,907

 

 

 

156,254

 

 

 

13,199,282

 

 


 

ITEM 9.01 Financial Statements and Exhibits.

 

A copy of the Company’s earnings  release is furnished, but not filed, as Exhibit 99.1 hereto.

 

(d)         Exhibits

Exhibit Index

 

 

Exhibit No.     

Description                                                      

99.1

Press release issued on May 9, 2018

 

 

 


 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

Endocyte, Inc.

 

 

 

May 9, 2018

By:

/s/ Beth A. Taylor

 

 

Name: Beth A. Taylor

 

 

Title: Vice President of Finance and Chief Accounting Officer

 

 


Endocyte, Inc. (NASDAQ:ECYT)
Historical Stock Chart

1 Year : From Sep 2017 to Sep 2018

Click Here for more Endocyte, Inc. Charts.

Endocyte, Inc. (NASDAQ:ECYT)
Intraday Stock Chart

Today : Thursday 20 September 2018

Click Here for more Endocyte, Inc. Charts.

Latest ECYT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20180920 23:53:17